Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify has developed oral, small molecules that can potentially reduce calcification by enhancing the activity of the ABCC6 protein, a key disease mechanism in CKD Dec. 22, 2025 -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, has entered a strategic researc

Numab to receive milestone payment Boehringer Ingelheim has advanced its novel multi-specific antibody for retinal diseases resulting from a collaboration with Numab into preclinical development Dec. 18, 2025 -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today that Boehringer Ingelheim has advanced its novel multi-specific antibody for the treatment of wet age-related macular degen

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 Dec. 18, 2025 -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded p

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time 18, 2025 -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical comp

Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs) through clinical proof of concept Atavistik Bio anticipates initiating its clinical trial in HHT in the first half of 2026 Dec. 18, 2025 -- Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics, today an

Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union Orphan designation confers market exclusivity, regulatory and financial benefits for medicines intended to treat rare diseases Recognizes both medical plausibility of the initial clinical data and that potravitug targets a life-threatening or chronically debilitating condition, BKPyV infection, which affects fewer than 5 in 10,000 people 18 December, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech compa

- Data expected in Q2 2026 - Dec. 18, 2025 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the completion of patient enrollment in REVITALYZ, a Phase 3 trial evaluating LUMRYZTM (sodium oxybate) extended-release oral suspension as a potential treatment for idiopathic hypersomnia (IH). REVITALYZ is a double-blind, placebo-controlled, randomized withdrawal, multicenter Phase 3 trial designed to evaluate th

Dec. 18, 2025 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led by Dr. Janette Vardy and Dr. Harya

Dec. 19, 2025 -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary trac

The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Dec. 19, 2025 -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced today that it has submitted a Pre-Request for Designation (Pre-RFD) to the U.S. Food and Drug Administration (FDA) for its PL-16 Viral Blocker, a non-pharmacological intranasal product designed to reduce exposure to airborne respiratory viruses, including influenza and cold vir